Factor Xa inhibitors: Today and beyond

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 272-281

  Walenga, Jeanine M ^a   Jeske, Walter P ^a   Hoppensteadt, Debra ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Anticoagulants; Antithrombotics; Factor Xa inhibitors

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTICOAGULANT AGENT; ANTISTASIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DPC 602; FIBRIN; FONDAPARINUX; HIRUDIN; IDRAPARINUX; KFA 1829; KFA 1982; N [1 (2 AMINOIMINOMETHYL 4 THIENYLMETHYL) 2 OXO 3 PYRROLIDINYL] 7 METHOXY N METHYL 2 NAPHTHALENESULFONAMIDE; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; RPR 128515; RPR 130737; SERINE PROTEINASE; SR 123781; SR 907107A; THROMBIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAGIN;

ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVATION; FIBRIN CLOT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INHIBITION KINETICS; KIDNEY FAILURE; LUNG EMBOLISM; NONHUMAN; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SEPSIS; SIDE EFFECT; STROKE; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS; CORONARY RESTENOSIS; DRUG MONITORING; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; THROMBOSIS;

EID: 0037962878     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Samama MM, Walenga JM, Kaiser B, Fareed J: Specific Factor Xa inhibitors. In: Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Verstraete M, Topol EJ, Fuster V (Eds), Lippincott-Raven, Brussels, Belgium (1997):173-188.
2. Weitz JI, Hirsh J: New antithrombotic agents. Chest (1998) 114(5 Suppl):715S-727S.
3. Stürzebecher J, Stürzebecher U, Vieweg H, Wagner G, Hauptmann J, Markwardt F: Synthetic inhibitors of bovine Factor Xa and thrombin comparison of their anticoagulant efficiency. Thromb Res (1989) 54(3):245-252.
4. Hauptmann J, Kaiser B, Nowak G, Stürzebecher J, Markwardt F: Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and Factor Xa inhibitors. Thromb Haemost (1990) 63(2):220-223.
5. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med (1996) 335(11):775-782.
6. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation (1996) 94(5):911-921.
7. Kaiser B, Hauptman J: Factor Xa inhibitors as novel antithrombotic agents: Facts and perspectives. Cardiovasc Drug Rev (1994) 12(3):225-236.
8. Kaiser B: Factor Xa versus Factor IIa inhibitors. Clin Appl Thrombosis/Hemostasis (1997) 3(1):16-24.
9. Meddahi S, Bara L, Uzan A, Samama MM: Pharmacologic modulation of human clots associated thrombin and prothrombinase activities by a direct anti Xa drug, r-hirudin and low molecular weight heparin. Haemostasis (1996) 26(Suppl):578.
10. Hoppensteadt D: Tissue factor pathway inhibitor as a modulator of post-surgical thrombogenesis. Experimental and clinical studies. Doctoral Thesis, University of London, London, UK, October (1996).
11. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 86(2):385-391.
12. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of Factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest (1993) 91(5):1877-1883.
13. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR: Role of thrombin compared with Factor Xa in the procoagulant activity of whole blood clots. Circulation (1995) 92(4):962-967.
14. McKenzie CR, Abendschein DR, Eisenberg PR: Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated Factor Xa. Arterioscler Thromb Vasc Biol (1996) 16(10):1285-1291.
15. Schwartz RS, Holmes DR Jr, Topol EJ: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol (1992) 20(5):1284-1293.
16. Kanthou C, Benzakour O: Cellular effects of thrombin and their signaling pathways. Cell Pharmacol (1995) 2:293-302.
17. Benzakour O, Kanthou C: Cellular and molecular events in atherogenesis: Basis for pharmacological and gene therapy approaches to restenosis. Cell Pharmacol (1996) 3:7-22.
18. McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M, Barry W, Gimple LW, Powers ER, Owens GK: Thrombin and vascular smooth muscle cell proliferation: Implications for atherosclerosis and restenosis. Semin Thromb Hemost (1996) 22(2):139-144.
19. Ko FN, Yang YC, Huang SC, Ou JT: Coagulation Factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest (1996) 98(6):1493-1501.
20. Gasic GP, Arenas CP, Gasic TB, Gasic GJ: Coagulation Factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA (1992) 89(6):2317-2320.
21. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasuk GP, Haber HL, Powers ER, Roberts WC, Sarembock IJ: Specific Factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation (1994) 89(3):1262-1271.
22. Schwartz RS, Holder DJ, Holmes DR, Veinot JP, Camrud AR, Jorgenson MA, Johnson RG: Neointimal thickening after severe coronary artery injury is limited by short-term administration of a Factor Xa inhibitor. Results in a porcine model. Circulation (1996) 93(8):1542-1548.
23. Creasey AA, Reinhart K: Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med (2001) 29(7 Suppl):S126-129.
24. Abraham E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med (2000) 28(9 Suppl):S31-33.
25. Chiron Corp: Chiron announces results of phase III study of tifacogin in severe sepsis.Press Release 21 November (2001).
26. Corvas International Inc: Corvas International presents results of phase IIa clinical trial of rNAPc2 anticoagulant in elective angioplasty. Press Release 05 December (2001).
27. Corvas International Inc: Programs & markets: Cardiovascular. Company World Wide Web Site 01 March (2003). http://www.corvas.com/programs-markets.html
28. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for Factor Xa. Thromb Haemost (1994) 71 (3):314-319.
29. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA: Antithrombotic effects of orally active synthetic antagonist of activated Factor X in nonhuman primates. Circulation (1995) 92(3):485-491.
30. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M: DX-9065a, an orally active, specific inhibitor of Factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost (1995) 74(2):635-639.
31. Yamazaki M, Asakura H, Saito M, Aoshima K, Morishita E, Matsuda T: Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of Factor Xa against experimental disseminated intravascular coagulation in rats. Thromb Haemost (1995) 73(Suppl):1312.
32. Hara T, Yokoyama A, Morishima Y, Kunitada S: Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective Factor Xa inhibitor. Thromb Res (1995) 80(1):99-104.
33. Kaiser B, Jeske W, Walenga JM, Fareed J: Inactivation of Factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinolysis (1999) 10(8):495-501.
34. Herbert JM, Bernat A, Dol F, Hérault JP, Crepon B, Lormeau JC: DX 9065A a novel, synthetic, selective and orally active inhibitor of Factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther (1996) 276(3):1030-1038. This paper describes many of the basic characteristics of DX-9065a, a Factor Xa inhibitor that is at a relatively more advanced stage in clinical development.
35. Tanabe K, Morishima Y, Shibutani T, Terada Y, Hara T, Shiohara Y, Aoyagi K, Kunitada S, Kondo T: DX-9065a, an orally active Factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thromb Haemost (1999) 81(5):828-834.
36. Kaiser B, Paintz M, Scholz O, Kunitada S, Fareed J: A synthetic inhibitor of Factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Thromb Res (2000) 98(2):175-185.
37. Herbert J-M, Bono F, Hérault J-P, Michaux C, Nestor A-L, Guillemot J-C, Altieri D, Schaeffer P: Activation of endothelial cells by Factor Xa reveals a new mode of activation of the PAR-2 receptor. Thromb Haemost (1999) 82(Suppl 1):693.
38. Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fujita M, Ikeda Y: Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific Factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther (1999) 66(3):258-264. This paper describes many of the human pharmacological characteristics of DX-9065a, a Factor Xa inhibitor that is at a relatively more advanced stage in clinical development.
39. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA et al: First experience with direct Factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation. Circulation (2002) 105(20):2385-2391. This paper describes the clinical safety and efficacy of DX-9065a.
40. Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, Light DR: Effects of ZK-807834, a novel inhibitor of Factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol (2000) 35(5):796-805.
41. Schering AG: Joint Projects by Schering. Company World Wide Web Site 22 March (2001). http://www.schering.de
42. Leamy AW, Luettgen JM, Wong PC, Reilly TM, Pinto DJ, Wexler RR, Wright MR, Knabb RM: Pharmacokinetics and antithrombotic efficacy of the selective Factor Xa inhibitor DPC 423 in dogs. Thromb Haemost (2001) (Suppl):Abs P1608.
43. Wong PC, Crain EJ, Watson CA, Zaspel AM, Lam PY, Pinto DJ, Wexler RR, Knabb RM: Antithrombotic and bleeding time effects of DPC423, an orally-active Factor Xa inhibitor, in rabbits. Circulation (2002) 106(20):598.
44. Hara K, Honma T, Nagano R, Matuzawa A, Akahane S, Kitazawa M: Antithrombotic effects of a selective Factor Xa (FXa) inhibitor KFA-1411, on the venous thrombosis model and less bleeding effects in rats. Jpn J Pharmacol (1999) 79(Suppl 1):P279.
45. Morgan SR, Bentley RG, Bostwick JS, Kasiewski CJ, Heran C, Brown KD, Colussi DJ, Chu V, Green D, Choi SYM, Pauls W et al: Antithrombotic efficacy of RPR130737: A novel inhibitor of coagulation Factor Xa. Thromb Haemost (1999) 82:ABS 818
46. Pruitt JR, Bostrum L, Galemmo RA, Wong PC, Wright MR, Bai S, Knabb RM, Wexler RR Discovery of DPC602: Ortho-substituted phenylpyrazoles as potent, orally bioavailable inhibitors of Factor X. American Chemical Society (2001) 221:Abs MEDI-049.
47. Kawasaki T, Sato K, Hirayama F, Koshoi H, Taniuchi Y, Matsumoto Y: Comparative studies of an orally-active Factor Xa inhibitor, YM-60828, with various antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost (1998) 79(4):859-864.
48. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J: Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res (1997) 86(1):1-36. This paper describes many of the basic characteristics of fondaparinux sodium.
49. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G: Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-Factor Xa activity. Biochem Biophys Res Commun (1983) 116(2):492-499.
50. Sinay P, Jaquinet JE, Petitou M et al: Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res (1984) 132(Suppl):C5-C9.
51. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinay P, Jacquinet JC, Torri G: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1-4)-O-(β-D-glu copyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-α-D-glucopyranosyl)-(1-4 )-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res (1986) 147(2):221-236.
52. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res (1987) 46(2):187-198.
53. Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-Factor Xa activity. Thromb Res (1988) 51(1):23-33.
54. Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC, Meuleman DG: Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost (1990) 63(2):265-270.
55. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J: Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs (2002) 11(3):397-407. This paper describes many of the basic characteristics as well as the first clinical experiences of fondaparinux sodium including its solely anti-Factor Xa activity.
56. Petitou M, Van Boeckel CA: Chemical synthesis of heparin fragments and analogues. Fortschr Chem Org Naturst (1992) 60:143-210.
57. Van Boeckel CA, Beetz T, Vos JN, De Jong AJ, Van Aelst SF, Van Den Bosch RH, Mertens JM, Van Der Vlugt FA: Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem (1985) 4:293-321.
58. Petitou M, Lormeau JC, Choay J: A new synthetic pentasaccharide with increased anti-Factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Res (1993) 19(Suppl 2):143-146.
59. Visser A, Buiting MT, Van Dinther TG, Van Boeckel CAA, Grootenhuis PG, Meuleman DG: The AT-III binding affinities of a series of synthetic pentasaccharide analogues. Thromb Haemost (1991) 65(Suppl):1296.
60. Meuleman DG, Hobbelen PM, Van Dinther TG, Vogel GM, Van Boeckel CA, Moelker HC: Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide. Semin Thromb Hemost (1991) 17(Suppl 1):112-117.
61. Van Amsterdam RG, Vogel GM, Visser A, Kop WJ, Buiting MT, Meuleman DG: Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol (1995) 15(4):495-503.
62. Walenga JM, Bara L, Hoppensteadt D, Choay J, Fareed J, Samama M: AT III as a rate limiting factor for the measurement of pentasaccharide in laboratory assays. Thromb Haemost (1991) 65(Suppl):1314.
63. Lormeau JC, Hérault JP, Herbert JM: Antithrombin-mediated inhibition of Factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost (1996) 76(1):5-8.
64. Dol F, Gaich C, Petitou M et al: The antithrombotic activity of synthetic pentasaccharides and fraxiparine is closely correlated with their respective ability to alter thromboplastin-triggered thrombin generation ex vivo. Thromb Haemost (1993) 69(Suppl):655.
65. Béguin S, Choay J, Hemker HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost (1989) 61(3):397-401.
66. Lormeau JC, Hérault JP: Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin, and a synthetic ATIII-binding pentasaccharide. Thromb Haemost (1993) 69(2):152-156.
67. Lormeau JC, Hérault JP: The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of Factor Xa. Thromb Haemost (1995) 74(6):1474-1477.
68. Walenga JM, Koza MJ, Lewis BE, Pifarré R: Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thrombosis/Hemostasis (1996) 2(Suppl 1):S21-S27.
69. Crépon B, Donat F, Bârzu T, Hérault JP: Pharmacokinetic (PK) parameters of AT binding pentasaccharides in three animal species: Predictive value for humans. Thromb Haemost (1993) 69(Suppl):654.
70. Walenga JM, Fareed J: Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide. Semin Thromb Hemost (1985) 11(2):89-99.
71. Boneu B, Necciari J, Cariou R, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T et al: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost (1995) 74(6):1468-1473.
72. Turpie AG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (2001) 344(9):619-625. This paper describes an early clinical trial of fondaparinux sodium.
73. Turpie AG: Efficacy of the first synthetic Factor Xa inhibitor, pentasaccharide ORG31540/SR90107a, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The PENTATHLON 2000 study. Thromb Haemost (2001) (Suppl):Abs OC48 This paper describes an early clinical trial of fondaparinux sodium.
74. Lassen MR: Efficacy of the first synthetic Factor Xa inhibitor, pentasaccharide ORG31540/SR90107a, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The EPHESUS study. Thromb Haemost (2001) (Suppl):Abs OC45 This paper describes an early clinical trial of fondaparinux sodium.
75. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 345(18):1298-1304. This paper describes an early
76. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 345(18):1305-1310. This paper describes an early clinical trial of fondaparinux sodium.
77. The Matisse Investigators: Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism - The Matisse Clinical Outcome studies. 44th Annual Meeting of the American Society of Hematology (2002):302.
78. Schiele FJ, Vuillemenot AR, Meneveau NF et al: Initial experience of a sulphated pentasaccharide, a pure Factor Xa inhibitor, in coronary angioplasty. Circulation (1996) 94(Suppl):I742.
79. Herbert JM, Herault JP, Bernat A, Van Amsterdam RG, Lormeau JC, Petitou M, Van Bouckel C, Hoffmann P, Meuleman DG: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91(11):4197-4205. This paper describes many of the basic characteristics occurring as a result of a modification of fondaparinux sodium, and the different pharmacokinetic properties that make it more acceptable for medical purposes.
80. Van Oers MHJ: A novel long-acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood (2002) 100(11):Abs 301
81. Akzo Nobel AV: Presentations: 3rd Analysts Pharma Day Presentations. 06-07 November (2002).
82. Hérault JP, Bernat A, Driguez PA, Duchaussoy P, Petitou M, Herbert JM: New synthetic heparin mimetics - Part 2: Biochemical and pharmacological properties. Thromb Haemost (1999) (Suppl):722.
83. Herbert JM, Hérault JP, Bernat A, Petitou M: SR123781A, a synthetic heparin mimetic. Thromb Haemost (1999) (Suppl):414.
84. Tobu M, Hoppensteadt D, Jeske W, Walenga J, Fareed J: Failure of international normalized ratio in the monitoring of antithrombin and anti-Xa drugs. Ann Hematol (2003) 82(Suppl 1):S85.
85. Wong PC, Crain EJ Jr, Nguan O, Watson CA, Racanelli A: Antithrombotic actions of selective inhibitors of blood coagulation Factor Xa in rat models of thrombosis. Thromb Res (1996) 83(2):117-126.
86. Nagahara T, Katakura S, Yokoyama Y et al: Design, synthesis and biological activities of orally active coagulation Factor Xa inhibitors. Eur J Med Chem (1995) 30(Suppl):140s-143s.
87. Yamashita T, Tsuji T, Matsuoka A, Giddings JC, Yamamoto J: The antithrombotic effect of synthetic low molecular weight human Factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res (1997) 85(1):45-51.
88. Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of Factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost (1994) 72(3):392-396.
89. Tanabe K, Terada Y, Shibutani T, Kunitada S, Kondo T: A specific inhibitor of Factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats. Thromb Res (1999) 96(2):135-143.
90. Hara T, Morishima Y, Kunitada S: Selective Factor Xa inhibitor, DX-9065a suppressed hypercoagulable state during haemodialysis in cynomologus monkeys. Thromb Haemost (1995) 73(Suppl);1311.
91. Kaiser B, Jeske W, Hoppensteadt D, Walenga JM, Fareed, J: Anticoagulant and antithrombotic effects of the synthetic heparin pentasaccharide and the direct Factor Xa inhibitor DX-9065a after iv administration in rabbits. Blood (1996) 88(Suppl 1):67b.
92. Chi L, Pen YW, Potoczak R, Gibson G, Hicks GM, Thomas E, Janiczek N, Juneau PL, Gallagher K, Leadley R: Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct Factor Xa inhibitor. Pharmacology (2002) 64(2):76-83.
93. Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR: A novel synthetic inhibitor of Factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther (2001) 296(2):567-572.
94. Bayer AG: Spring investor conference 2003. Company Presentation 13 March (2003).
95. Knabb RM, Bozarth TA, Leuttgen JM, Wong PC, Pinto DJ, Wexler RR, Reilly TM: In vitro characteristics of DPC 423, a novel anticoagulant specific for coagulation Factor Xa. Thromb Haemost (2001):Abs P1599
96. Yuji H, Takashi K, Harunobu M, Keiko M, Naoyuki M, Satoshi A: Characterization of a novel Factor Xa inhibitor KFA-1829: Effects on coagulation systems, experimental thrombosis model and bleeding. World Congr Pharmacol (2002) 24: Abs 21.2
97. Takashi K, Yuji H, Takashi N, Noboru K, Minoru F, Satoshi A, Masuo A: Antithrombotic effects of a novel oral active Factor Xa (FXa) inhibitor, KFA-1982 in vivo. World Congr Pharmacol (2002) 24: Abs 21.4
98. Wong PC, Crain EJ, Watson CA, Bai SA, Pruitt JR, Galemmo RA, Wexler RR, Knabb RM: Antithrombotic effects of DPC602, a potent and selective nonpeptide Factor Xa inhibitor, in rabbit models of thrombosis. Thromb Haemost (2001) (Suppl): Abs P1607
99. Czekaj M, Klein SI, Pauls HW, Gong Y, Maignan S, Guilloteau J.-P, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR et al.: Synthesis and SAR of a pyrrolidine-based series of Factor Xa inhibitors. American Chemical Society (2002) 224:Abs MEDI-285
100. Maignan S, Guilloteau JP, Pouzieux S, Choi Sledeski Y, Becker , Klein S, Ewing W, Pauls H, Spada A, Mikol V: Crystal structures of human Factor Xa complexed with potent inhibitors. J Med Chem (2000) 43(17):3226-3232.
101. Dunwiddie C, Thornberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E: Antistasin, a leech-derived inhibitor of Factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem (1989) 264(28):16694-16699.
102. Rigbi M, Jackson CM, Atamna H et al: FXa inhibitor from the saliva of the leech Hirudo medicinalis. Thromb Haemost (1995) 73(Suppl):1306.
103. Wang Z, Hebert D, Kaplan AV, Creasy A, Galluppi GR: Persistent inhibition to 12 hours of mural platelet thrombosis after a single local infusion of tissue factor pathway inhibitor at the site of angioplasty. Circulation (1996) 94(8):1-268.
104. Kaiser B, Hoppensteadt DA, Fareed J: Tissue factor pathway inhibitor for cardiovascular disorders. Exp Opin Emerging Drugs (2002) 5(1):73-88.
105. Broze GJ Jr: Tissue factor pathway inhibitor. Thromb Haemost (1995) 74(1):90-93.
106. Ostrem JA, Stringer S, Al-Obeidi F et al: Characterization of an orally available and highly specific synthetic Factor Xa inhibitor. Thromb Haemost (1995) 73(Suppl):1306.
107. Al-Obeidi F, Ostrem J: Factor Xa inhibitors. Exp Opin Ther Patents (1999) 9(7):931-953.
108. Jordan SP, Mao SS, Lewis SD, Shafer JA: Reaction pathway for inhibition of blood coagulation Factor Xa by tick anticoagulant peptide. Biochemistry (1992) 31(23):5374-5380.
109. Jordan SP, Waxman L, Smith DE, Vlasuk GP: Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation Factor Xa. Biochemistry (1990) 29(50):11095-11100.
110. Krishnaswamy S, Vlasuk GP, Bergum PW: Assembly of the prothrombinase complex enhances the inhibition of bovine Factor Xa by tick anticoagulant peptide. Biochemistry (1994) 33(25):7897-7907.
111. Vlasuk GP: Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation Factor Xa. Thromb Haemost (1993) 70(1):212-216.
112. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective Factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost (1991) 65(3):257-262.
113. Fioravanti C, Burkholder D, Francis B, Siegl PK, Gibson RE: Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res (1993) 71(4):317-324.
114. Lynch JJ Jr, Sitko GR, Lehman ED, Vlasuk GP: Primary prevention of coronary arterial thrombosis with the Factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost (1995) 74(2):640-645.
115. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK: Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation Factor Xa in a primate model of arterial thrombosis. Circulation (1991) 84(4):1741-1748.
116. Ørvim U, Barstad RM, Vlasuk GP, Sakariassen KS: Effect of selective Factor Xa inhibition on arterial thrombus formation triggered by tissue factor/Factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol (1995) 15(12):2188-2194.
117. Mellott MJ, Stranieri MT, Sitko GR, Stabilito II, Lynch J, Vlasuk GP: Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective Factor Xa inhibitor, in a canine model of femoral arterial thrombolysis. Fibrinolysis (1993) 7:195-202.
118. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective Factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation (1992) 85(2):805-815.
119. Lefkovitz J, Malycky JL, Rao JS, Hart CE, Plow EF, Topol EJ, Nicolini FA: Selective inhibition of Factor Xa is more efficient than Factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Coll Cardiol (1996) 28(7):1858-1865.
120. Vlasuk GP, Bergum PW, Brunck TK et al. Anticoagulant repertoire of hematophagous nematodes. Thromb Haemost (1995) 73(Suppl):1305.